Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity.
about
JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expressionComparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION studySpotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to dateProtective Effect of Ethanolic Extract of Seeds of Moringa oleifera Lam. Against Inflammation Associated with Development of Arthritis in RatsCombined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy aloneSoluble Siglec-9 suppresses arthritis in a collagen-induced arthritis mouse model and inhibits M1 activation of RAW264.7 macrophagesPoint mutation of tyrosine 759 of the IL-6 family cytokine receptor, gp130, augments collagen-induced arthritis in DBA/1J mice.Circadian rhythm of serum interleukin-6 in rheumatoid arthritisClinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study.Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis.Association between inflammatory biomarkers and bone mineral density in a community-based cohort of men and womenLeucine-rich alpha 2 glycoprotein promotes Th17 differentiation and collagen-induced arthritis in mice through enhancement of TGF-β-Smad2 signaling in naïve helper T cells.Ultrasensitive Label-Free Sensing of IL-6 Based on PASE Functionalized Carbon Nanotube Micro-Arrays with RNA-Aptamers as Molecular Recognition Elements.Anti-interleukin 6 receptor antibody treatment in rheumatic disease.Interleukin-6 and rheumatic diseases.The correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients.The paradigm of IL-6: from basic science to medicineInflammatory markers in population studies of aging.Cadherin-11 regulates fibroblast inflammationReduction of interleukin-6 expression in human synoviocytes and rheumatoid arthritis rat joints by linear polarized near infrared light (Superlizer) irradiation.Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.Evidence of different mediators of central inflammation in dysfunctional and inflammatory pain--interleukin-8 in fibromyalgia and interleukin-1 β in rheumatoid arthritisA multi-nutrient supplement reduced markers of inflammation and improved physical performance in active individuals of middle to older age: a randomized, double-blind, placebo-controlled study.The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis.The timing of glucocorticoid administration in rheumatoid arthritis.Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.Effectiveness of workplace rehabilitation interventions in the treatment of work-related upper extremity disorders: a systematic review.A Dual Target-directed Agent against Interleukin-6 Receptor and Tumor Necrosis Factor α ameliorates experimental arthritis.Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.Levels of Neopterin and other Inflammatory Markers in Obese and Non-Obese Patients with Polycystic Ovary Syndrome.The role of interleukin 6 in the pathophysiology of rheumatoid arthritisThe therapy of autoimmune diseases by anti-interleukin-6 receptor antibody.Rheumatoid arthritis: an overview of new and emerging therapies.Immunization against an IL-6 peptide induces anti-IL-6 antibodies and modulates the Delayed-Type Hypersensitivity reaction in cynomolgus monkeys.Interleukin-6 in aging and chronic disease: a magnificent pathwayChemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys.Novel therapies for rheumatoid arthritis.Circulating interleukin-6 and rheumatoid arthritis: A Mendelian randomization meta-analysis.Krüppel-Like Factor 4 Is a Regulator of Proinflammatory Signaling in Fibroblast-Like Synoviocytes through Increased IL-6 Expression.
P2860
Q24316553-C9B8FB0A-F131-4698-A53D-54EDB9DA72DFQ24630541-73250C0C-16FD-4FB4-A3BA-74EBFE5E0BCDQ28076558-1B470D97-017D-410D-B749-439F6C5513C3Q28298994-6B1F7993-2328-4A2E-B4DB-533FC4F7047BQ28710288-4EED62DB-667A-4581-91F7-3558CC1C5FC6Q28828456-5B5D7254-C5CF-4AE8-A888-E8341EDCA7B5Q33410688-5692BD3D-7FB3-448B-9BEB-9F7A7FD7971AQ33566549-7BD052B8-D2E9-43A8-A6DC-8CC7EA12E36BQ33578257-E580A67E-6D1B-4110-970D-3C86923CFFC7Q33658743-ECAD21EC-FF5A-46A3-BAB3-C1AC8066A66EQ33800888-91AD656B-69BB-417C-AB3E-23676466DCB8Q33802290-64A62150-9BF1-4A6B-8027-A012BF10E502Q33844812-3E179963-1830-4E8B-9068-AC98DFBE4C6DQ34071253-83CF7F8B-18A6-47BA-9BA0-1FF25E9FB043Q34160235-397E89C0-1FB8-4D4B-B400-DCC385E96DFFQ34474506-F9ABD50B-AEB1-4492-ACEC-6D3594824A97Q34731226-56C5DB5D-AF8C-4D84-83C8-B53D3629765FQ34995451-8A97DA57-8B48-408E-8AA6-83452C92DBEBQ35002899-0F15EF16-B202-4B24-8C7E-8CEEA7ACA654Q35025084-FB7531FA-0B71-4F1B-9A53-19F6D18FE299Q35183631-2D92D9EC-99B4-4E57-A138-60970F6768F8Q35213524-4E2510E9-B5F9-4026-9E92-FCF3B51C2B1CQ35232961-4EBFDEF9-5F29-4B4A-AFC0-E6AD5558E8A3Q35429154-6954DA20-56EA-44C6-8533-0617777205A9Q35546903-2965A385-8683-432E-903B-DDFD4E5786C6Q35609892-6B56CFCC-56F8-492B-B52C-A481448F36BDQ35724900-D5BE5E5B-4B9F-4708-82E5-D7DEF05A195DQ35783336-D0074D3D-4D43-45F5-AAAB-0B1105EAB7F2Q35913704-A7DB7594-66E4-434A-8A95-600D79F34709Q35954629-D0390B6D-6B15-4EBF-B118-8ED08A05807EQ35994143-4B48549C-A141-4808-8628-1C3B5D6A6531Q36059484-9D5B97F3-60A8-4AF1-80A9-5118A7213D11Q36150505-BA85E497-F9EC-4AE0-B78F-E06B3B2D5146Q36160669-260B8F0B-940E-4613-A250-237D83D9E0E7Q36499879-F6A94508-3BE2-45FA-BC7D-59979AC31FD3Q36518670-BCD53D77-73CF-46F7-8304-20E2AD6C482FQ36579912-C2CA3030-6077-4562-A48C-A016092CA922Q36623081-DA2DDD21-F6FD-4D3F-B570-161A994E37E6Q37003697-10F79686-B5AC-41BE-A21C-0D5F2A141CF0Q37054152-604818D3-D65E-4347-931A-FA065CFBE4E8
P2860
Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity.
description
1993 nî lūn-bûn
@nan
1993 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի մարտին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Serum interleukin 6 levels in ...... y indices of disease activity.
@ast
Serum interleukin 6 levels in ...... y indices of disease activity.
@en
Serum interleukin 6 levels in ...... y indices of disease activity.
@nl
type
label
Serum interleukin 6 levels in ...... y indices of disease activity.
@ast
Serum interleukin 6 levels in ...... y indices of disease activity.
@en
Serum interleukin 6 levels in ...... y indices of disease activity.
@nl
prefLabel
Serum interleukin 6 levels in ...... y indices of disease activity.
@ast
Serum interleukin 6 levels in ...... y indices of disease activity.
@en
Serum interleukin 6 levels in ...... y indices of disease activity.
@nl
P2093
P2860
P356
P1476
Serum interleukin 6 levels in ...... y indices of disease activity.
@en
P2093
P2860
P304
P356
10.1136/ARD.52.3.232
P407
P577
1993-03-01T00:00:00Z